Biotech
GC Therapeutics
GC Therapeutics raises $65M Series A at $280M valuation
$65M
Total Raised
Series A
Latest Round
2022
Founded
60+
Employees
Cambridge, MA
1 min read
Quick Facts
Valuation
$280M
Latest Round Size
$65M
Latest Round Date
November 2024
GC Therapeutics: Series A Funding Round
GC Therapeutics has successfully raised $65M in Series A funding, reaching a valuation of $280M.
Company Overview
Cell therapy-based medicine developer for cancer treatment
Funding Details
The Series A round was led by Arch Venture Partners, with participation from Venrock.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2022
- Employees: 60+
- Category: Biotech
Investment
GC Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Arch Venture Partners: Verified investor in Series A
- Venrock: Verified investor in Series A
Key Investors
Arch Venture Partners
Lead Investor
Verified investor in Series A
Venrock
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Editorial Team
Oct 8, 2025
1 min read•$153M